Evidence map›Paper›PMID 38579075›Full record

ReviewMedicine2024

Advances in the application of traditional Chinese medicine during the COVID-19 recovery period: A review.

Weixin Zhang, Linlin Ma, Wei Xie, Xingxing Li, Juhua Zhang, Ji Sun

Abstract readReview
In one paragraph

Review in Medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Weixin ZhangCollaborative Innovation Center for Biomedicines, Shanghai University of Medicine and Health Sciences, Shanghai, China.
Linlin MaSchool of Medical Technology, Shanghai University of Medicine and Health Sciences, Shanghai, China.
Wei XieSchool of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai, China.
Xingxing LiSchool of Pharmacy, Shanghai University of Medicine and Health Sciences, Shanghai, China.
Juhua ZhangCollaborative Innovation Center for Biomedicines, Shanghai University of Medicine and Health Sciences, Shanghai, China.
Ji SunCollaborative Innovation Center for Biomedicines, Shanghai University of Medicine and Health Sciences, Shanghai, China.ORCID 0000-0002-6092-1632

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since the emergence of the Coronavirus Disease 2019 (COVID-19) outbreak, significant advancements has been made in research, from limited knowledge about the disease to the development of a vaccine. Although the severity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) appears to be decreasing and the threat of COVID-19 is waning, there have been widespread concerns about persistent symptoms or sequelae experienced by some patients even after recovering from COVID-19. Traditional Chinese medicine (TCM) has shown favorable treatment outcomes during the onset of COVID-19, and extensive studies have been carried out to explore the efficacy of TCM interventions during the COVID-19 recovery period. The purpose of this review is to comprehensively analyze these studies and provide new insights for the prevention and treatment of the post-COVID-19 condition.

Indexed as

COVID-19Drugs, Chinese HerbalCOVID-19 Drug TreatmentHumansMedicine, Chinese TraditionalSARS-CoV-2Drugs, Chinese Herbal

Identifiers

PMID38579075
PMCPMC10994423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.